Unicycive Stock Plunges 19.1% Amid Reverse Split

On June 17, 2025, Unicycive's stock experienced a significant drop of 19.1% in pre-market trading, marking a notable decline in its share price.

Unicycive Therapeutics, Inc. recently announced a reverse stock split, which is expected to take effect on June 20, 2025. This move is likely to impact the company's stock price and trading dynamics, as shares will begin trading on a split-adjusted basis.

Following the earnings report, Unicycive Therapeutics' stock price decreased by 6.667%. This decline could be attributed to various factors, including investor sentiment and market conditions.

HC Wainwright reaffirmed a "buy" rating and issued a $9.00 target price on shares of Unicycive Therapeutics in a research report on May 28, 2025. This positive outlook from the analyst may have influenced investor decisions and contributed to the stock's performance.

Unicycive Therapeutics has also provided updates on its new drug application for Oxylanthanum Carbonate, which is intended to treat a specific medical condition. This development is crucial for the company's future prospects and could impact its stock price as investors assess the potential success of the drug.